Navigation Links
The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch

- Long-form web-based PSA ("Life. Lessons. Legacy.") features Carnegie-Mellon Professor's fight against pancreatic cancer and underscores his call-to-action for additional research into nation's fourth leading

cancer killer - PSA debuts on heels of Lustgarten Foundation's limited online book offer as seen on ABC Primetime with Diane Sawyer, where 5,000 free copies of "The

Last Lecture" were given to the public - Short-form (:30) PSA will air on major cable and television stations,

directing viewers to long-form PSA online

- The Lustgarten Foundation is nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to


BETHPAGE, N.Y., April 17 /PRNewswire/ -- The Lustgarten Foundation for Pancreatic Cancer Research, the nation's largest private foundation dedicated to supporting pancreatic cancer research, announced the debut of a new web- based long-form PSA featuring Dr. Randy Pausch. In the PSA, Dr. Pausch and his wife, Jai, share their thoughts about coping with a diagnosis of pancreatic cancer. Dr. Pausch speaks about the urgent need for additional research into the nation's fourth deadliest cancer and expresses concern that his children may someday face this deadly disease.

Said Dr. Robert Vizza, Lustgarten Foundation President, "Pancreatic cancer is an insidious disease because there is are no reliable tests to detect it early, when the chances for a cure are greatest. The disease is also aggressive and highly resistant to standard treatments."

Said Dr. Randy Pausch, "There have been too few advances in pancreatic cancer and, as a result, patients have limited options. For the sake of generations to come, we need to change the course of this disease. Only by giving the best and brightest scientific minds access to the resources they need will we find better treatments and, ultimately, a cure."

Said Kerri Kaplan, Lustgarten Foundation Executive Director, "The Lustgarten Foundation is committing millions of dollars for promising research precisely because the scientific method is our best hope in the fight against pancreatic cancer. We are proud to have the incredible partnership of the Pausch family, and we thank them for sharing their experience and serving as an inspiration to others."

The PSA is supported by an educational grant from Genentech and OSI Pharmaceuticals. View the PSA online at

SOURCE The Lustgarten Foundation for Pancreatic Cancer Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
4. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
5. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
6. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
7. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
8. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
9. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
10. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):